Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial

Bipolar Disorders

Volumn 17, Issue 6, 2015, Pages 606-614

  Arabzadeh, Somayeh ^a   Ameli, Niusha ^b   Zeinoddini, Atefeh ^a   Rezaei, Farzin ^b   Farokhnia, Mehdi ^a   Mohammadinejad, Payam ^a   Ghaleiha, Ali ^c   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjunctive therapy; Celecoxib; Clinical trial; COX 2 inhibitor; Inflammation; Mania

Indexed keywords

CARBAMAZEPINE; CELECOXIB; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LITHIUM; LORAZEPAM; MOOD STABILIZER; OLANZAPINE; PLACEBO; RISPERIDONE; VALPROIC ACID; CYCLOOXYGENASE 2 INHIBITOR;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ANTIINFLAMMATORY ACTIVITY; APPETITE DISORDER; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; FATIGUE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; MOOD DISORDER; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; SCORING SYSTEM; YOUNG MANIA RATING SCALE; DRUG COMBINATION; INFLAMMATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; MALE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84941024143     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12324     Document Type: Article

References (44)

1. Kessler RC, Akiskal HS, Ames M et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006; 163: 1561-1568.
2. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143-151.
3. Raju TN. The Nobel chronicles. 1927: Julius Wagner-Jauregg (1857-1940). Lancet 1998; 352: 1714.
4. McNamara RK, Lotrich FE. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother 2012; 12: 1143-1161.
5. Breunis MN, Kupka RW, Nolen WA et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003; 53: 157-165.
6. Brietzke E, Stertz L, Fernandes BS et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214-217.
7. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord 2004; 82: 309-313.
8. Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002; 59: 592-596.
9. Lee HJ, Rao JS, Rapoport SI, Bazinet RP. Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 239-246.
10. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64: 233-252.
11. Akhondzadeh S, Jafari S, Raisi F et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26: 607-611.
12. Muller N, Schwarz MJ, Dehning S et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-684.
13. Musil R, Schwarz MJ, Riedel M et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression - no influence of celecoxib treatment. J Affect Disord 2011; 134: 217-225.
14. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012; 141: 308-314.
15. Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23: 87-94.
16. Aid S, Langenbach R, Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 2008; 5: 17.
17. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 2012; 27: 405-413.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
20. Amrollahi Z, Rezaei F, Salehi B et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 2011; 129: 327-331.
21. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8: 485-489.
22. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res 2014; 215: 540-546.
23. Shahmansouri N, Farokhnia M, Abbasi SH et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord 2014; 155: 216-222.
24. Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. J Psychiatr Res 2014; 59: 125-131.
25. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014; 53C: 23-34.
26. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology, 7th edn. Philadelphia, PA: Elsevier Saunders, 2012.
27. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
28. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104: 91-95.
29. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90: 263-267.
30. Ortiz-Domínguez A, Hernández ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9: 596-602.
31. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012; 136: 110-116.
32. Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord 2001; 64: 185-193.
33. Cunha AB, Andreazza AC, Gomes FA et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2008; 258: 300-304.
34. Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 2013; 65: 105-142.
35. Basselin M, Kim HW, Chen M et al. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res 2010; 51: 1049-1056.
36. Knijff EM, Breunis MN, Kupka RW et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord 2007; 9: 743-753.
37. Kargar M, Yousefi A, Mojtahedzadeh M et al. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly 2014; 144: w13880.
38. Padol IT, Hunt RH. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology 2010; 49: 837-843.
39. Fields C, Drye L, Vaidya V, Lyketsos C; ADAPT Research Group. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry 2012; 20: 505-513.
40. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-185.
41. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-910.
42. Muller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010; 121: 118-124.
43. Muller N, Ulmschneider M, Scheppach C et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 2004; 254: 14-22.
44. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005; 57: 1594-1596.